RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q1 2019
Top Holdings50 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ROCKET PHARMACEUTICALS INC | 16M | $280.3M | 19.1% | $17.54 | 0.00% | 1 qtr | New 96 |
PTC THERAPEUTICS INC | 2.5M | $94.6M | 6.5% | $37.64 | 0.00% | 1 qtr | New 93 |
DICERNA PHARMACEUTICALS INC | 6.2M | $91.2M | 6.2% | — | — | 1 qtr | New 93 |
ALNYLAM PHARMACEUTICALS INC | 835,873 | $78.1M | 5.3% | $93.45 | 0.00% | 1 qtr | New 93 |
BRISTOL-MYERS SQUIBB CO | 1.5M | $72.8M | 5.0% | $36.69 | 0.00% | 1 qtr | New 83 |
PROQR THRAPEUTICS N V | 3.7M | $51.6M | 3.5% | $13.87 | 0.00% | 1 qtr | New 82 |
MASIMO CORP | 363,569 | $50.3M | 3.4% | $138.28 | 0.00% | 1 qtr | New 82 |
| 1.7M | $48.2M | 3.3% | — | — | 1 qtr | New 82 | |
VERICEL CORP | 2.5M | $43.6M | 3.0% | $17.51 | 0.00% | 1 qtr | New 76 |
LIVANOVA PLC | 435,136 | $42.3M | 2.9% | $97.25 | -16.22% | 1 qtr | New 76 |
ACHILLION PHARMACEUTICALS IN | 13.7M | $40.7M | 2.8% | — | — | 1 qtr | New 76 |
AVI BIOPHARMA INC | 338,199 | $40.3M | 2.8% | $119.19 | 0.00% | 1 qtr | New 76 |
MYOKARDIA INC | 706,570 | $36.7M | 2.5% | — | — | 1 qtr | New 76 |
AXONICS INC | 1.5M | $36.5M | 2.5% | — | — | 1 qtr | New 76 |
ADVERUM BIOTECHNOLOGIES INC | 6.3M | $32.8M | 2.2% | — | — | — | — |
ESTABLISHMENT LABS HLDGS INC | 1.3M | $31.9M | 2.2% | $24.04 | 0.00% | 1 qtr | New 76 |
Agenus Inc. | 9.9M | $29.4M | 2.0% | — | — | — | — |
ARROWHEAD PHARMACEUTICALS IN | 1.5M | $28M | 1.9% | $18.35 | 0.00% | 1 qtr | New 67 |
REGENXBIO INC | 451,182 | $25.9M | 1.8% | $57.31 | 0.00% | 1 qtr | New 66 |
STANDARD BIOTOOLS INC | 1.9M | $25.7M | 1.8% | $13.29 | 0.00% | 1 qtr | New 66 |
RTW INVESTMENTS, LP manages $1.5B across 50 positions as of Q1 2019. Top holdings: RCKT (19.1%), PTCT (6.5%), DRNA (6.2%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 50 new positions, 0 exits, 0 increased. Top move: RCKT (NEW, conviction 96). Portfolio: $1.5B across 50 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer